General MedicationsIntravesical, UreteralStandard
CYSTO-CONRAY
IOTHALAMATE MEGLUMINE
Standard Dose
43%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview CYSTO-CONRAY is listed in Drugs@FDA under application 017057 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient IOTHALAMATE MEGLUMINE Form and strength Solution; Intravesical, Ureteral - 43% Sponsor LIEBEL-FLARSHEIM Submission history Latest submission status date: 2013-12-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview CYSTO-CONRAY is listed in Drugs@FDA under application 017057 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient IOTHALAMATE MEGLUMINE Form and strength Solution; Intravesical, Ureteral - 43% Sponsor LIEBEL-FLARSHEIM Submission history Latest submission status date: 2013-12-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.